Primary mutations in the EGFR sequence such as the L858R are known to be involved in tumour development and drug resistance, especially in non-small-cell lung cancer (NSCLC)6,7, accounting for more than 80% of highly fatal lung cancers8,.9 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.